Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.32 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.32 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85234 | 0.78 | — | — | |
| SCHEMBL1462570 | 0.78 | — | — | |
| SCHEMBL3997234 | 0.77 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1TSHRTDP1 | |
| SCHEMBL3931699 | 0.76 | — | — | |
| SCHEMBL20442265 | 0.76 | — | — | |
| Bromide SCHEMBL28416542 | 0.74 | — | — | |
| SCHEMBL1462685 | 0.74 | — | — | |
| SCHEMBL27020207 | 0.74 | — | — | |
| SCHEMBL12244313 | 0.72 | CA12 (0.38) | CA12CA2CA3CA4CA6 | |
| SCHEMBL14844783 | 0.72 | CA12 (0.53) | CA12CA2CA3CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663449-B2 | — | — | 2017-05-30 | — | — | US | disclosed |
| WO-2017020010-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | NEUROPORE THERAPIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-2695608-B1 | Lipid containing formulations | ARBUTUS BIOPHARMA CORP (CA) | 2016-11-23 | — | — | EP | disclosed |
| US-20160333003-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-17 | — | — | US | disclosed |
| US-20140121393-A1 | LIPID CONTAINING FORMULATIONS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-05-01 | — | — | US | disclosed |
| EP-2518067-A1 | Derivatives of N-[(1H-pyrazol-1-YL)aryl]-1H-indole or 1H- indazole-3-carboxamide and their therapeutic uses as P2Y12 antagonists | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-8034376-B2 | Lipid containing formulations | Alnylam Pharamaceticals, Inc. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | BANK OF AMERICA, N.A. | 2009-01-22 | — | — | US | disclosed |
| US-6255495-B1 | KILLING HYPOXIC TUMOR CELLS AND TREATING DERMATOLOGICAL DISEASES IN WARM-BLOODED ANIMALS VIA ADMINISTERING RADIOSENSITIZING AMOUNT OF ELECTRON-AFFINIC-DIAMINE | FLORIDA STATE UNIVERSITY | 2001-07-03 | — | — | US | disclosed |
| US-6060604-A | FOR RADIOTHERAPY TECHNIQUES, INCREASING TUMOR RADIOSENSITIVITY | FLORIDA STATE UNIVERSITY (US) | 2000-05-09 | — | — | US | disclosed |
| US-6057453-A | OXIDATION, FORMING RADIOSENSITIZING DIAMINES, REDUCTION | FLORIDA STATE UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121393-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CA12 4627/4885CA2 4453/4885CA3 4765/4885 |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CA12 4627/4885CA2 4453/4885CA3 4765/4885 |
| US-20160333003-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | UPF1, NUDT21, RNMT | CA12 4627/4885CA2 4416/4885CA3 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.